IFM Investors Pty Ltd Purchases 1,910 Shares of Humana Inc. (NYSE:HUM)


Share on StockTwits

IFM Investors Pty Ltd increased its position in shares of Humana Inc. (NYSE:HUM) by 17.6% in the 4th quarter, HoldingsChannel reports. The fund owned 12,791 shares of the insurance provider’s stock after acquiring an additional 1,910 shares during the period. IFM Investors Pty Ltd’s holdings in Humana were worth $5,248,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of HUM. Kestra Advisory Services LLC acquired a new position in Humana during the 3rd quarter valued at approximately $1,142,000. Catalyst Private Wealth LLC purchased a new stake in Humana during the third quarter worth $25,000. American Research & Management Co. purchased a new stake in Humana during the third quarter worth $29,000. Tortoise Investment Management LLC purchased a new stake in Humana during the third quarter worth $31,000. Finally, Prospera Financial Services Inc purchased a new stake in Humana during the third quarter worth $39,000. Hedge funds and other institutional investors own 85.10% of the company’s stock.

Humana stock opened at $416.02 on Thursday. Humana Inc. has a 12-month low of $208.25 and a 12-month high of $474.70. The stock has a market cap of $55.06 billion, a P/E ratio of 13.33, a PEG ratio of 1.72 and a beta of 0.84. The company has a 50-day moving average price of $407.81 and a 200 day moving average price of $409.61. The company has a current ratio of 1.81, a quick ratio of 1.81 and a debt-to-equity ratio of 0.38.

Humana (NYSE:HUM) last released its quarterly earnings data on Tuesday, November 3rd. The insurance provider reported $3.08 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.81 by $0.27. The firm had revenue of $20.08 billion during the quarter, compared to analysts’ expectations of $18.59 billion. Humana had a net margin of 5.58% and a return on equity of 22.74%. Humana’s revenue was up 23.6% compared to the same quarter last year. During the same period last year, the business earned $5.03 earnings per share. As a group, analysts forecast that Humana Inc. will post 18.66 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, January 29th. Shareholders of record on Thursday, December 31st will be paid a dividend of $0.625 per share. This represents a $2.50 annualized dividend and a yield of 0.60%. The ex-dividend date of this dividend is Wednesday, December 30th. Humana’s dividend payout ratio (DPR) is presently 13.99%.

In other Humana news, Director David A. Jr/Ky Jones sold 5,000 shares of the stock in a transaction dated Thursday, December 17th. The shares were sold at an average price of $392.76, for a total transaction of $1,963,800.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Timothy S. Huval sold 746 shares of the stock in a transaction dated Wednesday, December 16th. The stock was sold at an average price of $387.27, for a total transaction of $288,903.42. Following the transaction, the insider now directly owns 7,435 shares of the company’s stock, valued at approximately $2,879,352.45. The disclosure for this sale can be found here. Company insiders own 0.42% of the company’s stock.

HUM has been the subject of a number of research analyst reports. Royal Bank of Canada upgraded shares of Humana from a “sector perform” rating to an “outperform” rating and upped their price objective for the stock from $429.00 to $479.00 in a research report on Monday, January 4th. Stephens upped their price objective on shares of Humana from $450.00 to $490.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 4th. They noted that the move was a valuation call. BidaskClub upgraded shares of Humana from a “sell” rating to a “hold” rating in a research report on Saturday, January 9th. Credit Suisse Group upped their price objective on shares of Humana from $423.00 to $465.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 4th. Finally, SVB Leerink reduced their price objective on shares of Humana from $505.00 to $500.00 and set an “outperform” rating for the company in a research report on Monday, November 30th. Eight investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $456.55.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Article: Net Asset Value

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.